At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 241 enrolled
Drug / intervention
Ruxolitinib Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib Cream and Vehicle Cream for Atopic Dermatitis. Completed, enrolled 241 participants across 94 sites in 14 countries.
Detailed Summary
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Belgium, Bulgaria, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedFeb 2024
Enrollment StartApr 2024
Primary CompletionMay 2025
Study CompletionOct 2025
TodayJul 2026
First PostedFeb 2, 2024
Enrollment StartApr 26, 2024
Primary CompletionMay 21, 2025
Study CompletionOct 17, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.4 years ago
Interventions
Ruxolitinib Creamdrug
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Vehicle Creamdrug
Matching vehicle cream applied topically to the affected area as a thin film twice daily.